ArticleClinical and translational science2023

Evidence-based rationale for low dose nivolumab in critically ill patients with sepsis-induced immunosuppression.

Demy A C van den Haak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.